Glucosamine, a popular supplement widely taken by older adults to manage joint pain and arthritis, has been linked to a 25 percent higher likelihood of progression from mild cognitive impairment to dementia, according to new research published in Nature Metabolism. Prevention reported that the study investigated electronic health records alongside animal models and human brain tissue to uncover how the supplement interacts with an overactive biological pathway in brains affected by Alzheimer’s disease.
University of Florida Researchers Track Patient Records
Researchers at the University of Florida analyzed health records gathered between 2012 and 2024 to determine whether glucosamine use correlated with Alzheimer’s disease and related dementias, as Health and Me reported. The investigation zeroed in on patients diagnosed with mild cognitive impairment or Alzheimer’s disease. Approximately 8 percent of patients in both groups reported taking glucosamine. This translation captured 2,750 people with mild cognitive impairment and 1,896 individuals who already had Alzheimer’s disease or a related dementia.
After adjusting for age, sex, and demographic factors, the analysis revealed that patients with mild cognitive impairment who used glucosamine had a 25 percent higher likelihood of progressing to dementia compared to non-users. Among individuals who already carried a dementia diagnosis, glucosamine use was associated with a 25 percent higher risk of death during the study period, according to the findings.
Mouse Models and Brain Tissue Reveal Hyperglycosylation Mechanisms
To understand the biological underpinnings, the research team studied genetically modified mice and human brain tissue to examine a cellular process called glycosylation. Glycosylation involves the attachment of sugar chains, known as glycans, to proteins inside cells. This process dictates how proteins fold, travel, and function, which is critical to how neurons communicate.
ScienceAlert noted that molecular biologist Matt Gentry explained that brain cells and proteins in Alzheimer’s patients build up extra sugar coatings. When researchers analyzed postmortem brain tissue from people who died with Alzheimer’s disease, they measured an overactive sugar-tagging system compared to healthy tissue. Senior author Ramon C. Sun noted that glucosamine allows the body to make sugar chains. While healthy brains process this normally, brains already altered by neurodegenerative disease experience hyperglycosylation, which interferes with the proteins neurons rely on for signaling.
Neurologists Urge Caution While Awaiting Controlled Clinical Trials
Despite the statistical association found in health records, study authors and independent specialists emphasize that the research does not prove glucosamine causes dementia or accelerates its onset. Clifford Segil, a neurologist at Providence Saint John’s Health Center, called the findings interesting but stated they do not cause enough clinical concern to stop administering the supplement to arthritis patients right away. Sun echoed this perspective, stressing that the study did not examine healthy individuals and that context matters significantly.
Health and Me noted that Matt Gentry described the electronic health record data as provocative while confirming it remains an association rather than proof of causality. Sun recommended that patients do not panic or alter their supplement routines without consulting a physician, adding that a prospective clinical trial stands as the essential next step to determine whether glucosamine directly impacts human disease progression.
Clarifying causation and study participant numbers for glucosamine use
Does the new study prove that glucosamine causes dementia?
No. The research identified an association between glucosamine use and faster disease progression in patients who already had mild cognitive impairment or Alzheimer’s disease, but it did not establish direct causation.
How many people in the study were taking glucosamine?
Approximately 8 percent of the patient cohort examined at University of Florida Health facilities reported using the joint supplement, representing 2,750 people with mild cognitive impairment and 1,896 people with Alzheimer’s or related dementias.
What biological process links glucosamine to brain changes?
Researchers identified glycosylation, a normal cellular process where sugar chains attach to proteins, as becoming overactive in Alzheimer’s brains. Glucosamine introduces raw materials directly into this pathway, which may interfere with neuronal communication.
What are the next steps for researchers studying this link?
Study authors hope to conduct prospective clinical trials and track dementia patients who previously used glucosamine and then discontinued it to observe how their disease progression compares to those who remain on the supplement.
Related reading